Review

Vitamin D and Chronic Diseases

Hanmin Wang¹², Weiwen Chen¹²,*, Dongqing Li¹², Xiaoe Yin¹², Xiaode Zhang², Nancy Olsen³, Song Guo Zheng²³,*

¹Division of Endocrinology, Qujing First Hospital at Kunming Medical University, Qujing, Yunan 655400, China
²Expert Workstation, Qujing First Hospital at Kunming Medical University, Qujing, Yunan 655400, China
³Division of Rheumatology, Milton S Hershey Medical Center at Penn State University, Hershey, PA17033, USA

[Received June 25, 2016; Revised October 19, 2016; Accepted October 21, 2016]

ABSTRACT: Vitamin D is one of the essential nutrients to sustain the human health. As a member of the steroid hormone family, it has a classic role in regulating metabolism of calcium and a non-classic role in affecting cell proliferation and differentiation. Epidemiological studies have shown that 25OHD deficiency is closely associated with common chronic diseases such as bone metabolic disorders, tumors, cardiovascular diseases, and diabetes. 25OHD deficiency is also a risk factor for neuropsychiatric disorders and autoimmune diseases. 25OHD deficiency is highly prevalent in the world. It is therefore necessary to know the adverse health effects of 25OHD deficiency, and to design interventions and early treatments for those who are likely to have low levels of 25OHD.

Key words: Vitamin D, chronic diseases, early prevention, deficiency

Many studies have demonstrated that Vitamin D has multiple effects on biological processes regulating calcium and phosphorus metabolism as well as effects on cell proliferation, differentiation, apoptosis, immune regulation, genome stability, and neurogenesis. Recent studies have also found that Vitamin D is closely associated with cardiovascular diseases, diabetes, cancers, autoimmune diseases, infectious diseases, and others [1, 2]. Many experts now believe that Vitamin D (especially with biological activities of 1, 25(OH)2D3) should be considered a hormone rather than one of the conventional nutritional vitamins.

Vitamin D overview

Vitamin D in the human body is mainly derived from skin after ultraviolet light exposure and from dietary sources. Vitamin D is derived from 7-dehydrocholesterol, which is converted in the skin by ultraviolet light band B (UVB) to Vitamin D3 (cholecalciferol), an inactive precursor. More than 90% of systemic Vitamin D originates from the skin and around 10% from food intake [1].

There are two main forms of Vitamin D, Vitamin D3 (cholecalciferol) and Vitamin D2 (ergocalciferol). Following the absorption from the intestines or/and the synthesis by skin, Vitamin D is transferred to the liver where it is metabolically converted into 25(OH)D in the liver, 25 (OH)D has a further metabolic conversion in the kidney. The active metabolites 1, 25 (OH) 2D3 and 24R (OH) D can be converted by 25 (OH) 1α-hydroxy-D (CYP27B1) or 24R hydroxylase (CYP24A1 or CYP24) in the kidney, respectively.

Vitamin D, an essential nutrient to sustain health, is a member of the steroid nuclear hormone superfamily, and...
was first discovered to be able to prevent rickets in children [3]. Further research has found that Vitamin D has broader physiological functions. Currently the biological effects of Vitamin D are divided into two categories: First, in calcium and phosphorus metabolism, considered the classical activity; and second, the non-classical or alternative pathway that mainly affects immune function, inflammation, anti-oxidation, antifibrosis and others [4-7], as well as inhibitory effects on the many kinds of malignancies [7-9].

1, 25 (OH) 2 D3 is an autocrine hormone. The 1α-hydroxy enzyme is also widely expressed in non-kidney cells, such as osteoblasts, monocytes, macrophages, neuron cells, pancreatic cells, breast cancer, and colon cancer cells. 25 (OH) D in these cells can be directly related to the active form of metabolic enzymes and is not affected by the classical hormonal regulation of calcium and phosphorus metabolism [10]. As 25 (OH) D is much more stable than 1,25(OH)2D3 in the body, 25 (OH)D has been considered as an important indicator of Vitamin D levels in humans [11].

Vitamin D has multiple functions and target organs. Vitamin D and the nuclear vitamin D receptor (VDR) after binding can influence the expression of many genes. VDR is widely expressed in the kidney, immune cells, bone cells and other cells [12]. Studies have shown that the levels and activities of Vitamin D are closely related to the occurrence and development of many chronic conditions, such as malignancies, autoimmune diseases, metabolic disorders, and infectious disease [13].

Once formed, Vitamin D3 is ejected out of the keratinocyte plasma membrane and is drawn into the dermal capillary bed by Vitamin D Binding Protein (DBP). Vitamin D ingested is then incorporated into chylomicrons, which are released into the lymphatic system [2, 14], and enter the venous blood, where they bind to DBP and lipoproteins and are transported to the liver [14, 15]. The 25(OH)D bound to DBP is filtered by the kidneys and is reabsorbed in the proximal renal tubules by megalin cubilin receptors [14, 16].

25 (OH) D in circulating is mostly in 25-(OH) D-DBP complex form [17]. In a study of DBP gene knockout mice, DBP was shown to protect 25-(OH) D and 1, 25 (OH) 2 D 3 from degradation by kidney [18], to adjust the systemic levels of Vitamin D [19]. Additionally, susceptibility to a variety of malignant tumors including breast cancer, prostate cancer, colorectal cancer, is also related to VDBP reduction [20]. Other studies have found that 25OHD not only works through the VDR, but also through combining with Vitamin D dependent calcium binding protein [21]. Some of these studies have found that in islet beta cells, 25OHD can adjust the Vitamin D receptor and Vitamin D dependent calcium binding protein, thereby promoting synthesis and secretion of insulin [22, 23].

The criteria for Vitamin D levels

Although there are different methods and criteria on defining Vitamin D levels, the criteria Holic proposed has been widely accepted. In this proposal, it is suggested as Vitamin D deficiency if the level of 25 (OH) D in circulating blood in human is less than or equal to 20 ng/ml (50 nmol/L), insufficiency if between 21 to 29 ng/ml and sufficiency if greater than or equal to 30 ng/ml [24].

Based on this criterion, adult 25OHD deficiency was found in both developing and developed countries. For example, about 40% population suffer from 25OHD deficiency in China in winter season, and the incidence of 25OHD deficiency is higher among women than in men, and higher in elderly group than young one [25]. In general, Chinese elderly population has a low level of Vitamin D with 25 (OH) D averaging of 14-16 ng/ml and Vitamin D deficiencies accounted for 83%-93%, of which about 30% have a serious shortage. Vitamin D level continues to decrease along increasing age [25]. Centers of Diseases Control and Prevention (CDC) reported that 32% of children and adults have a circulating concentration of 25OHD less than 20 ng/mL. Reports from Mexico, South America, Europe, Asia, India and Africa suggest that more than 50% of the world population is at risk for 25OHD deficiency [14, 15, 26]. High rates of biochemical 25OHD deficiency or insufficiency among healthy individuals have been reported in large-scale studies from all parts of the world: The United States [27], Canada [28], South America [29], Europe [30], Australia [31], the Middle East [32], South Asia [33], and Africa [34].

25OHD level is also generally low in infants, children and women in menopause. The proportions of deficiency and insufficiency among these populations vary between 30% to 80%, and even teenagers in the sunny plateau area. Recent study observed that population in sunny plate area still have an incidence of 25OHD deficiency between 23%-44% [35]. There is a low 25OHD level in the populations from developing countries even in sunny climates [36], suggesting that the 25OHD deficiency is not only due to the lack of sunshine.

Relationship between 25OHD deficiency and a variety of chronic diseases

In recent years, accumulating epidemiological and laboratory evidence has documented that 25OHD deficiency is correlated to the onset and progression of many chronic diseases.
Vitamin D and cancer

Vitamin D binding protein (VDBP) as a carrier of Vitamin D can be combined with Vitamin D and its metabolites to play a crucial role in transport to the cell. Deficiency in VDBP also affects the function of Vitamin D. For example, studies have demonstrated that low level of VDBP is related to a variety of malignant tumors, including breast, prostate and colorectal [20, 37-41]. Both prospective and retrospective epidemiologic studies indicate that levels of 25OHD below 20 ng/ml are associated with a 30 to 50% increased risk of incident colon, prostate, and breast cancer, along with higher mortality from these cancers [42-46]. The report that postmenopausal women who increased their vitamin D intake by 1100 IU of vitamin D 3 reduced their relative risk of cancer by 60 to 77% is a compelling reason to be vitamin D sufficient [47]. Similarly, a recent study observed that 25 (OH) D progressively decline during the course of the development of liver fibrosis, cirrhosis to liver cancer [37].

Vitamin D and cardiovascular diseases

The pathogenesis of chronic cardiovascular disease is affected by a variety of risk factors. Clinical studies found that in addition to high cholesterol, smoking, obesity, high blood pressure and diabetes, low serum levels of 25OHD are also closely related to the occurrence of cardiovascular diseases [48]. In addition, hypertension incidence may be related to low levels 25OHD [49]. The role of vitamin D in the cardiovascular system is noticeable since the presence of its receptors not only the heart but also in the entire cardiovascular system [50]. The 1, 25(OH)2D3 active form of Vitamin D combines with VDR and then regulates the expression of many genes [51, 52].

Vitamin D metabolites act on multiple domains of cardiovascular function including those related to inflammation, thrombosis and the renin angiotensin aldosterone system (RAAS) pathways [53]. Vitamin D has well known effects in endothelial cells, where it stimulates nitric oxide (NO) production [54], protects against oxidative stress [58] and prevent endothelial apoptosis [55, 56] by diverse genomic and non-genomic pathways. As endothelial function has emerged as a key factor for initiation and progression of atherosclerotic process, vitamin D may contribute for reversing atherosclerosis burden [57]. A broad series of in vitro studies have also suggested that vitamin D and its analogs consistently suppress pro-inflammatory cytokines and increases anti-inflammatory cytokines, which mechanisms involved seem to be related to the inhibition of NF-kB and p38 pathways by VDRs [58].

Vitamin D also seems to present an anticoagulant activity [59], through the regulation of the expression of pro-coagulant and antifibrinolytic factors. Low levels of Vitamin D lead to the activation and releasing of pro-inflammatory cytokines which then increases the risk of CVD by mediating endothelial dysfunction and arterial wall stiffness [60]. Large epidemiological studies have shown that 25OHD deficiency is a signal of cardiovascular disease risk [61]. Mechanisms likely include the elimination of Vitamin D receptor in macrophage, which then triggers insulin resistance and mononuclear phagocytic cells of cholesterol, thereby accelerating atherosclerosis in mice [62].

Vitamin D and diabetes

25OHD deficiency has been shown to be related to the development of diabetes [63]. Recent studies have shown that 25 (OH) D levels are negatively correlated to prevalence of diabetes mellitus type 2(T2DM), islet beta cell function, insulin resistance, body fat, and BMI levels [64, 65]. Conversely, 25(OH)D levels were positively correlated with insulin sensitivity. 25OHD deficient individuals have a higher insulin resistance and type 2 diabetes risk [66].

1, 25 (OH) 2 D3 can be combined with Vitamin D3 receptor on the islet β cells, increasing insulin sensitivity, inhibiting inflammatory factors, alleviating chronic inflammation process of the pancreas to improve the function of islet β cells [67]; Additionally, it also inhibits the action of the renin-angiotensin system, which promotes insulin secretion [68]. Vitamin D supplementation can improve islet β cell function and glucose tolerance [69].

Studies have found that Vitamin D dependent calcium binding protein is present not only in islet β cells, also in PP cells and D cells, and is most abundant in islet α cells [70]. Its principal action is to regulate the concentration of intracellular calcium by Vitamin D dependent calcium binding protein, thus affecting the endocrine and metabolic processes in the various cells of the pancreas. Other studies have found that glucagon hormone release was significantly higher in islets isolated from 25OHD deficient mice than in those isolated from mice with normal levels of Vitamin D, following in vitro stimulation with 10 mmol/L arginine or hypoglycemia (blood glucose control is less than 1.7 mmol/L). Moreover, supplementation with 1,25 (OH) 2 D3 can make glucagon restored to normal levels [71]. Thus, 25OHD deficiency not only suppresses insulin secretion through weakening the islet β cell function, but also elevates blood sugar through enhancing islet α cell function.

Vitamin D and immune system diseases

Vitamin D can play a role in regulating immune function,
inhibiting inflammatory reactions and autoimmune diseases [72]. 1, 25(OH) 2D3 combined with Vitamin D receptor plays an important role in immune cell biology [73].

Many immune cells in the human body such as monocytes, macrophages, dendritic cells, T cells, and B cells express VDR. Vitamin D3 in combination with VDR in T cells can inhibit the activity of Th1 cells, thereby reducing the CD4 + T cells to release IL-2, interferon γ and tumor necrosis factor (TNF) α, β, and to delay the progress of chronic inflammatory autoimmune diseases [74]. In addition, it can promote the differentiation of mononuclear cells into macrophages, and strengthen their chemokine production and ability to control infection [75]. It also inhibits the major histocompatibility complex II (MHC II) expression on antigen-presenting cells to prevent the activation of immune system [76]. Vitamin D also induces B cell proliferation and the secretion of immunoglobulins E and M, leading to the formation of memory B cells and B cell apoptosis promotion [77]. These results have demonstrated that 1, 25-(OH)2D3 has an important role in the anti-inflammatory response and immune regulation.

**Vitamin D and neuropsychiatric disorders**

Vitamin D is closely related to the metabolism of CYP27B1. CYP27B1 was known as CYP27B1. CYP27B1 is expressed in neurons and glial cells in both of fetus and adult, especially in the substantia nigra supra optic and hypothalamus paraventricular tissues. Additionally, VDR is highly expressed in the hypothalamus, pons, basal ganglia, hippocampus, as well as in developing brain tissues, suggesting that Vitamin D may be involved in the development and function of the brain [78].

It is likely that Vitamin D participates in the process of neurotransmitter synthesis, inflammation, and calcium balance. Other studies have documented that Vitamin D can protect nerve cells by its antioxidant effect [79]. A cohort study including 56366 American women between ages 50 to 79 years has shown that high levels of Vitamin D intake can significantly reduce the risk of depression, providing additional evidence to suggest that 25OHD deficiency affects the neuropsychiatric disorders [80].

There are a variety of similar studies relating 25OHD deficiency with increased risk for depression [81, 82], Alzheimer disease [83], epilepsy [84] and neurocognitive decline [85, 86]. Evidence suggests that 1,25(OH)2D3 could increase calcium binding protein expression [87], although this could not be shown in all studies [88]. 1,25(OH)2D3 could also act by increasing serotonin levels in the brain [89]. Furthermore 1,25(OH)2D3 has also been demonstrated to stimulate amyloid-β phagocytosis and clearance by macrophages in Alzheimer patients [90]. This may help explain the association between neurocognitive decline, dementia, depression, and Alzheimer diseases and a high prevalence of 25OHD deficiency [81, 82, 86, 90, 91].

**Vitamin D and other diseases**

The outcome of 25OHD deficiency in terms of osteoporosis, osteomalacia and increased fracture risk is well known [92, 93]. Furthermore, vitamin D may be relevant in the physiopathology of chronic liver diseases because of its effect on the immune system and its anti-fibrotic effect [94-96]. A high percentage of chronic hepatitis C virus infection patients (46% to 92%) have low 25OHD levels [97-99], and more than 25% those were suffering from severe 25OHD deficiency [97-99]. In a recent clinical study of adults with non-alcoholic fatty liver disease (NAFLD), Targher et al [100] showed that the 25OHD levels had an effect on the development of hepatic steatosis and in the severity of the histological lesion. A possible role of vitamin D has also implicated in several other diseases, including multiple sclerosis [101], psoriasis [102], OA [103], and chronic kidney disease [104]. Taken together, 25OHD levels affect the multiple diseases.

**Conclusion**

25OHD deficiency predominately affects the occurrence and development of many chronic diseases. With an aging population, the numbers of patients with osteoporosis, cardiovascular diseases, cancers, diabetes and other chronic diseases dramatically increase. Similarly, the incidence of neurological and psychiatric diseases is also increasing year by year. These outcomes result in the loss of life of the population, reduced quality of life and significant social and economic burdens. Since these chronic diseases lack specific treatment or the treatment effects are not curative, strategies for the control of chronic diseases should focus on the prevention. Vitamin D deficiency is associated with chronic disease. Hence, it is challenging to clarify whether vitamin D deficiency is the cause or only the consequence of various chronic diseases. We need to continue to study Vitamin D.

**Acknowledgements**

This work was in part supported by a grant for expert workstation project from the Department of Science and Technology in Yunnan Province in China.
References

[1] Holick MF (2004). Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr, 80: 1678s-1688s

[2] Mathieu C, Badenhoop K (2005). Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab, 16: 261-266

[3] Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008). Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics, 122: 398-417

[4] Handono K, Sidarta YO, Pradana BA, Nugroho RA, Hartono IA, Kalim H, et al. (2014). Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones, 46: 189-198

(2015). Correction: Treatment with Vitamin D/MOG Association Suppresses Autoimmune Encephalomyelitis. PLoS One, 10: e0131260

[6] Van Belle TL, Vanherwegen AS, Feyaerts D, De Clercq P, Verstuyf A, Korf H, et al. (2014). 1,25-Dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLoS One, 9: e109194

[7] Reddy KK (2013). Reply to Glossmann: vitamin D compounds and oral supplementation methods. J Invest Dermatol, 133: 2649

[8] Takahashi H, Hatta Y, Iriyama N, Hasegawa Y, Uchida H, Nakagawa M, et al. (2014). Induced differentiation of human myeloid leukemia cells into M2 macrophages by combined treatment with retinoic acid and 1alpha,25-dihydroxyvitamin D3. PLoS One, 9: e113722

[9] Zhang Z, Zhang H, Hu Z, Wang P, Wan J, Li B (2014). Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells. Oncol Lett, 8: 1348-1354

[10] Henry HL (2011). Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab, 25: 531-541

[11] Hossein-nezhad A, Holick MF (2013). Vitamin D for health: a global perspective. Mayo Clin Proc, 88: 720-755

[12] Cantorna MT, Zhu Y, Froicu M, Wittke A (2004). Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr, 80: 1717s-1720s

[13] Ahmed SZ, Jaleel A, Hameed K, Qazi S, Suleman A (2015). DOES VITAMIN D DEFICIENCY CONTRIBUTE TO THE SEVERITY OF ASTHMA IN CHILDREN AND ADULTS? J Ayub Med Coll Abbottabad, 27: 458-463

[14] Holick MF (2007). Vitamin D deficiency. N Engl J Med, 357: 266-281

[15] Hossein-nezhad A, Holick MF (2012). Optimize dietary intake of vitamin D: an epigenetic perspective. Curr Opin Clin Nutr Metab Care, 15: 567-579

[16] Holick MF (2012). Vitamin D: extraskeletal health. Rheum Dis Clin North Am, 38: 141-160

[17] Kim SH, Choi GS, Nam YH, Kim JH, Hur GY, Kim SH, et al. (2012). Role of vitamin D-binding protein in isocyanate-induced occupational asthma. Exp Mol Med, 44: 319-329

[18] Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, et al. (1999). Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest, 103: 239-251

[19] Taes YE, Goemaere S, Huang G, Van Pottelbergh I, De Bacquer D, Verhasselt B, et al. (2006). Vitamin D binding protein, bone status and body composition in community-dwelling elderly men. Bone, 38: 701-707

[20] Weinstein SJ, Purdue MP, Smith-Warner SA, Mondl AM, Black A, Ahn J, et al. (2015). Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer, 136: E654-E664

[21] Hou JC, Min L, Pessin JE (2009). Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm, 80: 473-506

[22] Johnson JA, Grande JP, Roche PC, Kumar R (1994). Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol, 267: E356-E360

[23] Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C (2005). The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol, 349: 248-260

[24] Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005). Estimates of optimal vitamin D status. Osteoporos Int, 16: 713-716

[25] Chen W, Zhang X, Wang H, Zhang W, Xu Y, Zheng S (2015). The epidemic investigation of serum 25-hydroxy vitamin D levels in the adults in Qujing area of Yunnan province in China. Int J Clin Exp Pathol, 8: 9597-9601

[26] Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sembros CT (2011). Vitamin D status: United States, 2001-2006. NCHS Data Brief: 1-8

[27] Ginde AA, Liu MC, Camargo CA, Jr. (2009). Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med, 169: 626-632

[28] Genuis SJ, Schwalfenberg GK, Hiltz MN, Vaselenak SA (2009). Vitamin D status of clinical practice populations at higher latitudes: analysis and applications. Int J Environ Res Public Health, 6: 151-173

[29] Oliveri B, Plantalech L, Bagur A, Wittich AC, Rovai M, Haddad JG, et al. (1999). Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest, 103: 239-251

[30] Holick MF, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008). Vitamin D status, 1,25-dihydroxyvitamin D3, and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLoS One, 9: e109194
Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein MS, et al. (2003). Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc, 51: 1533-1538

Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, et al. (2004). Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health, 4: 38

Marwaha RK, Tandon N, Reddy DR, Aggarwal R, Singh R, Sawhney RC, et al. (2005). Vitamin D and bone mineral density status of healthy schoolchildren in northern India. Am J Clin Nutr, 82: 477-482

Daniels ED, Pettifor JM, Schnitzler CM, Moodley GP, Zachen D (1997). Differences in mineral homeostasis, volumetric bone mass and femoral neck axis length in black and white South African women. Osteoporos Int, 7: 105-112

Zhang Q, Xiao-Qi HU, Guo HX (2010). VITAMIN D NUTRITION STATUS IN CHINESE TIBETAN AND HAN NATIONALITY CHILDREN AND ADOLESCENTS. Modern Preventive Medicine, 37:465-467.

Unger MD, Cuppari L, Titan SM, Magalhaes MC, Sassaki AL, dos Reis LM, et al. (2010). Vitamin D status in a sunny country: where has the sun gone? Clin Nutr, 29: 784-788

Hammad LN, Abdelraouf SM, Hassanein FS, Kamei S, Kamiyama R (2000). 1alpha,25-dihydroxyvitamin D receptors and aminotransferase activity in liver of rats. J Nutr Biochem, 11: 788-793

Weinstein SJ, Mondul AM, Kopp W, Roger H, Virtamo J, Albanes D (2013). Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer, 132: 2940-2947

Mondul AM, Weinstein SJ, Virtamo J, Albanes D (2012). Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer, 107: 1589-1594

Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, et al. (2010). Vitamin D binding protein: a macromolecule activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One, 5: e13428

Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM (2009). Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 21: 990-995

Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al. (2005). Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol, 97: 179-194

Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. (2006). Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst, 98: 451-459

A honen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000). Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control, 11: 847-852

Feskanchich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, et al. (2004). Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev, 13:1502-1508

Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. (2006). The role of vitamin D in cancer prevention. Am J Public Health, 96: 252-261

Lappe JM, Travers-Gustafsson D, Davies KM, Recker RR, Heaney RP (2007). Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr, 85: 1586-1591

Lavie CJ, Dincicoltanionio JJ, Milani RV, O'Keeffe JH (2013). Vitamin D and cardiovascular health. Circulation, 128: 2404-2406

Ferder M, Inserra F, Manucha W, Ferder L (2013). The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system. Am J Physiol Cell Physiol, 304: C1027-C1039

Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. (2005). 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation, 111: 1666-1671

Fernandes dA, D. A. (2009). Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology, 34 Suppl 1: S265-S277

Stumpf WE (2012). Drugs in the brain—cellular imaging with receptor microscopic autoradiography. Prog Histochem Cytochem, 47: 1-26

Norman PE, Powell JT (2014). Vitamin D and cardiovascular disease. Circ Res, 114: 379-393

Borges AC, Feres T, Vianna LM, Paiva TB (1999). Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension, 34: 897-901

Uberti F, Lattuada D, Morsanuto V, Nava U, Bolis G, Vacca G, et al. (2014). Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways. J Clin Endocrinol Metab, 99: 1367-1374

Polidoro L, Properzi G, Marampon F, Gravina GL, Festuccia C, Di Cesare E, et al. (2013). Vitamin D protects human endothelial cells from H(2)O(2) oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res, 6: 221-231

Carvalho LS, Sposito AC (2015). Vitamin D for the prevention of cardiovascular disease: Are we ready for that? Atherosclerosis, 241: 729-740

Talmor Y, Berheim J, Klein O, Green J, Rashid G (2008). Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Invest, 38: 548-554

Ohsawa M, Koyama T, Yamamoto K, Hiroswa S, Kamei S, Kamiyama R (2000). 1alpha,25-
dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation, 102: 2867-2872

Brewer LC, Michos ED, Reis JP (2011). Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets, 12: 54-60

Pilz S, Gaksch M, O’Hartaiagh B, Tomaszchitz A, Marz W (2013). The role of vitamin D deficiency in cardiovascular disease: where do we stand in 2013? Arch Toxicol, 87: 2083-2103

Oh J, Riek AE, Darwech I, Funi K, Shao J, Chin K, et al. (2015). Deletion of macrophage Vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. Cell Rep, 10: 1872-1886

Harinarayan CV (2014). Vitamin D and diabetes mellitus. Hormones (Athens), 13: 163-181

Lim S, Kim MJ, Choi SH, Shin CS, Park KS, Jang HC, et al. (2013). Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects. Am J Clin Nutr, 97: 524-530

Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. (2013). Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med, 10: e1001383

Al-Timimi DI, Ali AF (2013). Serum 25(OH) D in Diabetes Mellitus Type 2: Relation to Glycemic Control. J Clin Diaqn Res, 7: 2686-2688

Baeke F, Gysemans C, Korf H, Mathieu C (2010). Vitamin D insufficiency: implications for the immune system. Pediatr Nephrol, 25: 1872-1886

Cheng Q, Li YC, Boucher BJ, Leung PS (2011). A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia, 54: 2077-2081

Kadowaki S, Norman AW (1984). Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest, 73: 759-766

Redecker P, Cetin Y (1997). Rodent pancreatic islet cells contain the calcium-binding proteins calcineurin and calretinin. Histochem Cell Biol, 108: 133-139

Bourlon PM, Faure-Dussert A, Billaudel B, Sutter BC, Tramu G, Thomasset M (1996). Relationship between calbindin-D28K levels in the A and B cells of the rat endocrine pancreas and the secretion of insulin and glucagon: influence of vitamin D3 deficiency and 1,25-dihydroxyvitamin D3. J Endocrinol, 148: 223-232

Jeffery LE, Qureshi OS, Gardner D, Hou TZ, Briggs Z, Soskic B, et al. (2015). Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function. PLoS One, 10: e0131539

Moreira TS, Hamadeh MJ (2010). The role of vitamin D deficiency in the pathogenesis of type 2 diabetes mellitus. E-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, 5: e155–e165

Rigby WF, Denome S, Fanger MW (1987). Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest, 79: 1659-1664

Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. (2007). IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol, 178: 7190-7198

Almerighi C, Sinistro A, Cavazza A, Ciprini C, Rocchi G, Bergamini A (2009). 1 Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine, 45: 190-197

Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE (2007). Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol, 179: 1634-1647

Harms LR, Burne TH, Eyles DW, McGrath JJ (2011). Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab, 25: 657-669

Kesby JP, Eyles DW, Burne TH, McGrath JJ (2011). The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol, 347: 121-127

Bertone-Johnson ER, Powers SL, Spangler L, Brunner RL, Michael YL, Larson JC, et al. (2011). Vitamin D intake from foods and supplements and depressive symptoms in a diverse population of older women. Am J Clin Nutr, 94: 1104-1112

Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW (2008). Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry, 65: 508-512

Jorde R, Sneve M, Figsenschau Y, Svartberg J, Waterloo K (2008). Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Inetrn Med, 264: 599-609

Annweiler C, Llewellyn DJ, Beauchet O (2013). Low serum vitamin D concentrations in Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis, 33: 659-674

Hollo A, Clemens Z, Kamondi A, Lakatos P, Szucs A (2012). Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav, 24: 131-133

Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC (2006). Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry, 14: 1032-1040

Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, et al. (2010). Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med, 170: 1135-1141

Eyles DW, Smith S, Kinobe R, Hewison M, McGrath Eyles DW, Smith S, Kinobe R, Hewison M, McGrath
[88] Jande SS, Goldenson B, Ghirmai S, Avagyan H, Zagh J, Abel K, et al. (2009). 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis, 17: 703-717

[89] Partonen T (1998). Vitamin D and serotonin in winter. Med Hypotheses, 51: 267-268

[90] Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zagh J, Abel K, et al. (2009). 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis, 17: 703-717

[91] Buell JS, Dawson-Hughes B, Scott TM, Weiner DE, Dallal GE, Qui WQ, et al. (2010). 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology, 74: 18-26

[92] Perez-Lopez FR (2007). Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas, 58: 117-137

[93] Looker AC, Mussolino ME (2008). Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res, 23: 143-150

[94] Adams JS, Hewison M (2008). Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab, 4: 80-90

[95] Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. (2011). Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut, 60: 1728-1737

[96] Neeman R, Abramovitch S, Sharvit E, Elad-Sfadia G, Haklai R, Klooq Y, et al. (2014). Vitamin D and S-farnesythyiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation. Dig Dis Sci, 59: 2462-2469

[97] Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. (2010). Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 51: 1158-1167

[98] Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermeiren J, et al. (2011). Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol, 54: 887-893

[99] Choudhary NS, Tomar M, Chawla YK, Bhadada SK, Khandelwal N, Dhiman RK, et al. (2011). Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci, 56: 3323-3327

[100] Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. (2007). Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 17: 517-524

[101] Embry AF, Snowdon LR, Vieth R (2000). Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol, 48: 271-272

[102] Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, et al. (2002). Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol, 147: 316-323

[103] Sanghi D, Mishra A, Sharma AC, Singh A, Natu SM, Agarwal S, et al. (2013). Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin Orthop Relat Res, 471: 3556-3562

[104] Nakagawa Y, Koizumi M, Fukagawa M (2015). Current Topics on Vitamin D. Vitamin D and chronic kidney disease. Clin Calcium, 25: 413-423